Amplify EASI Tactical Growth ETF
Limited financial coverage for EASI.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This exchange-traded fund (ETF) endeavors to achieve investment performance, specifically in terms of price movement and income generation, that closely aligns with the EASI Tactical Growth Index, before accounting for any associated fees and expenses. Typically, the fund commits at least 80% of its total assets, including assets acquired through borrowing, directly into the securities composing this underlying index. The index itself follows a particular methodology engineered to optimize risk-adjusted returns.
- IPO
- 2018
Get TickerSpark's AI analysis on EASI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $28.51
- 52W Low
- $18.71
- 50D MA
- $21.07
- 200D MA
- $21.07
- Beta
- 0.00
- RSI (14)
- 54
- Avg Volume
- 0
No earnings-call transcripts are available for EASI yet.
- Free Float
- 0.0%
- Shares Outstanding
- 501.33K
- Float Shares
- 0
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 06 | KLING S LEE | sell | 852 |
| Jan 31, 06 | KLING S LEE | sell | 8,438 |
| Jan 31, 06 | KLING S LEE | sell | 8,438 |
| Jan 31, 06 | KLING S LEE | sell | 8,438 |
| Jan 31, 06 | KLING S LEE | sell | 8,438 |
| Jan 31, 06 | KLING S LEE | sell | 8,438 |
| Aug 8, 88 | KLING S LEE | other | 0 |
| Aug 8, 88 | KLING S LEE | other | 0 |
| Aug 8, 88 | KLING S LEE | other | 0 |
| Mar 1, 05 | KLING S LEE | other | 8,438 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EASI coverage
Recent articles, reports, and earnings notes.
No research on EASI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EASI report →New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
gurufocus.com · Sep 30
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
gurufocus.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.